ZG006 plus ZG005 for advanced small cell lung cancer and neuroendocrine carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, multicenter Phase Ib/II trial gives the investigational agents ZG006 and ZG005 together to adults with advanced small cell lung cancer or neuroendocrine carcinoma to define safety and early activity. Eligible participants have histologically or cytologically confirmed disease, ECOG performance status 0-1, are aged 18-70, and have life expectancy over three months. The protocol includes dose and safety monitoring, imaging to measure tumor response, and collection of adverse event and survival data to establish a recommended phase II dose and preliminary efficacy signals. Enrollment and treatment are conducted at Sun Yat-sen University Cancer Center with scheduled clinical and radiologic follow-up per protocol.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Fully understand the study and voluntarily sign the informed consent form.
* Male or female 18-70 years of age.
* Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology.
* Eastern Cooperative Oncology Group (ECOG) 0 to 1.
* Life expectancy \> 3 months.

Exclusion Criteria:

* The investigator believes that the subject has other reasons that make them unsuitable for participation in this study.

Where it's running

• Sun Yat-sen University Cancer Center
  Guanzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Hewen Yin
• Email: yinhw@zelgen.com
• Phone: +86-0512-57309965

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Autologous B7-H3 CAR T Cells in Advanced Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

  This study tests a patient’s own B7-H3 CAR T cells to see if they can help people 18 and older whose small cell lung cancer or EPNEC has come back or hasn’t responded to prior treatment.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07509034

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• Treatment of small cell lung cancer and neuroendocrine carcinoma with ZG006

  This study is testing a new drug called ZG006 to see if it can help adults with small cell lung cancer or neuroendocrine carcinoma who have run out of other treatment options.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Zhengzhou, Henan · NCT05978284

• Tarlatamab in strong-performance-status small-cell lung cancer

  This trial tests whether tarlatamab can help people with extensive-stage small-cell lung cancer and poor health (ECOG 2) who have already had prior treatment.

  Recruiting at 8 sites Phase 2 AIO-Studien-gGmbH · Berlin and 7 other locations · NCT07803848

• Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers

  Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07783477

• Tarlatamab given under the skin vs by IV in extensive-stage small cell lung cancer after platinum therapy

  This trial tests whether subcutaneous tarlatamab works as well as the IV form for people with extensive-stage small cell lung cancer after platinum chemotherapy.

  Recruiting at 9 sites Phase 3 Amgen · Orlando, Florida and 8 other locations · NCT07778316

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.